淋巴结靶向 mKRAS 多肽疫苗胰腺癌随机 II 期 AMPLIFY-7P 试验未达主要终点
Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial
ESMO Congress 2026 报告的随机 II 期 AMPLIFY-7P 试验显示，在标准根治性治疗后 6 个月内的突变 KRAS 胰腺癌患者中，淋巴结靶向现成多肽疫苗未达到无病生存期主要终点。预设亚组分析显示，疫苗组在循环肿瘤 DNA 阴性患者和未接受过放疗的患者中无病生存期获益显著。
Nature Medicine, Published online: 23 October 2026; doi:10.1038/s41591-026-04734-7
As presented at the ESMO Congress 2026, in a randomized phase 2 trial evaluating an off-the-shelf lymph node-targeting peptide vaccine in patients with mutated KRAS pancreatic cancer within 6 months of standard curative intent therapy, the primary endpoint of disease-free survival was not met, but prespecified subgroup analyses showed significant disease-free survival benefit in the vaccine arm for patients with circulating tumor DNA-negative disease and in those without prior radiation treatment.
来源：Nature Medicine · nature.com